New Two-Part cancer drug enters first human tests
Disease control
Recruiting now
This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…
Phase: PHASE1 • Sponsor: Tagworks Pharmaceuticals BV • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC